在具有外分泌和神经内分泌成分的胃癌中生存和转移性淋巴结模式
Hu Ren1, Penghui Niu1, Zefeng Li1
1Department of Pancreatic and Gastric Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Annals of surgical oncology
|March 25, 2025
概括
神经内分泌癌 (NEC) 组件的淋巴结转移显著恶化了胃癌与共存的外分泌和神经内分泌组件 (GC-EN) 的存活率. 结合淋巴结数量和组成的新型N分期系统改善了GC-EN患者的预后准确性.
科学领域:
- 在瘤学瘤学.
- 胃肠病学 胃肠病学
背景情况:
- 胃癌与共存的外分泌和神经内分泌成分 (GC-EN) 是一种罕见的,攻击性的癌症亚型.
- 淋巴结转移组合对GC-EN患者存活率的影响尚不清楚.
研究的目的:
- 在GC-EN中调查淋巴结转移的预后意义,其细胞成分不同.
- 为GC-EN.EN开发和评估一个新的N分期系统.
主要方法:
- 对98名GC-EN患者 (2004-2020) 的回顾性分析.
- 将GC-EN分为NEC主导,混合腺核内分泌癌 (MANEC) 和AC主导亚型.
- 基于细胞组成的淋巴结的分类 (NEC,AC,MANEC).
主要成果:
- 淋巴结转移发生在72.48%的患者中.
- 与AC主导型相比,NEC主导型和MANEC型的淋巴结转移率高于AC主导型.
- NEC组件的淋巴结转移与更差的预后显著相关 (HR 2.341,P=0.023).
- 与AJCC系统 (0.719) 相比,新的N分期系统显示出更好的预后准确性 (C指数0.739).
结论:
- 神经内分泌癌 (NEC) 组件的淋巴结转移是GC-EN中的一个关键的负预后因素.
- 拟议的N分期系统,整合淋巴结数量和组成,为GC-EN患者提供了增强的预后分层.
- 这个系统可以指导GC-EN的个性化治疗策略.
相关概念视频
Tumor Progression
6.3K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.3K
Adaptive Mechanisms in Cancer Cells
5.8K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.8K
Metastasis
5.4K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.4K
Cancer Stem Cells and Tumor Maintenance
4.3K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
4.3K


